title: [What are the objectives of moderate to severe psoriasis treatment?].
abstract: Psoriasis is a potentially severe and highly disabling systemic disease. Over the last few years, large international randomized trials on biotherapies have made it possible to rigorously assess patients' quality of life. Moreover, combining patient groups has been organized in Europe and elsewhere, which has allowed large-scale studies structured around psoriasis patient expectations. A review of these studies provides information on patient expectations so that they can be transformed into therapeutic objectives. Through studies conducted on infliximab, it has been shown that this type of new treatment can respond to a large part of patient demand.
authors: Service de Dermatologie, Hôpital de l'Archet, Avenue St Antoine de Ginestière, 06100 Nice, France. ortonne@unice.fr
authors: J-P
authors: JP
authors: Ortonne
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000627:therapeutic use; D006801:Humans; D000069285:Infliximab; D011565:Psoriasis / Q000188:drug therapy / Q000503:physiopathology* / Q000523:psychology / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic; D012720:Severity of Illness Index
chemical_list: D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D000069285:Infliximab